natgillin/translations-raw huggingface dataset:
Pharmaceutical composition consisting of a therapeutically effective amount of desmopressin or a pharmaceutically acceptable salt thereof, one or several preservatives, antibacterial and antifungal agents, selected from parabens and salts or mixtures thereof, one or several acids for adjusting the pH of the composition and water, selected from the group consisting of hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, acetic acid and citric acid, and mixtures thereof, said pharmaceutical composition being a stable, liquid and flexible-dose composition of pH between 3.5 and 5.0 to be administered orally. 
Farmaceutski pripravak koji se sastoji od terapijski učinkovite količine dezmopresina ili njegove farmaceutski prikladne soli, jednog ili više konzervansa, antibakterijskih ili antifungalnih tvari, odabranih između parabena te njihovih soli ili mješavina, jedne ili više kiselina za podešavanje pH pripravka i vode, odabrano iz skupine koju čine klorovodična kiselina, dušična kiselina, fosforna kiselina, sulfatna kiselina, octena kiselina i limunska kiselina, i njihove mješavine, taj farmaceutski pripravak je stabilan i tekuć pripravak fleksibilne jačine s pH između 3.5 i 5.0 za oralnu primjenu.
The present invention concerns infant formula having a fat gradient which can be established by a sufficient amount of fat droplets with a diameter of 5-25 µm based on total weight of fat. 
Upotreba biljne masti, proteina i ugljikohidrata, u pripravi tekuće mliječne formule za dojenčad, naznačena time što najmanje 15%, težinski, masnih kapi ima promjer od 5-25 mikrometara, na osnovu ukupne težine masti za ishranu dojenčeta.
the crystalline hydrogen malonate salt of Compound I. Fig; cf. also 
Kristalinična vodik malonska sol Spoja I prema zahtjevu 1.
The capsule according to claim 2, wherein the perforation means (5) has the general shape of a contoured plate, and wherein the valve means (15) are arranged at the periphery of the plate. 
Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što sredstvo za probijanje (5) ima opći oblik hrapave ploče, te što ventil (15) se nalazi na rubu te ploče.
shaping the composition to form an extended release matrix formulation; and 
(b) oblikovanje sastava kako bi se formirala formulacija matrice s produljenim otpuštanjem; i
A method according to aspect #26 or aspect #27, wherein said third polymeric material is said polycarboxylic acid polymer that is at least partially neutralised, said method comprising dispersing a polycarboxylic acid polymer in a solvent, optionally with a buffer agent, and adding base to at least partially neutralise the polycarboxylic acid polymer to form the inner coating preparation. 
Postupak za koji se traži zaštita patentom u patentom zahtjevu 11 ili patentnom zahtjevu 12, spomenuti postupak sadrži disperziju polimera polikarboksilne kiseline u otapalu, izborno s puferskim sredstvom, i dodavanje baze da se barem delimično neutralizira polimer polikarboksilne kiseline da bi se formirao preparat unutarnje obloge.
The pharmaceutical composition of item 1 or 2, wherein said second binding domain specific for human CEA comprises at least the amino acid sequence "DRGLRFYFDY" (SEQ ID NO. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedena druga vežuća domena specifična za ljudski CEA u najmanju ruku sadrži aminokiselinski slijed "DRGLRFYFDY" (SEQ ID NO.
The fiber optic enclosure assembly as claimed in any of claims 1-13, wherein a position of the cable spool (37, 137) can be fixed such that it does not rotate relative to the housing (23, 123) once the desired length of first cable (22, 122) has been paid out. 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) 1z kutije sa optičkim kabelom prema Zahtjevu 1, koji dalje podrazumijeva fiksiranje položaja kalema (37, 137) kabela u odnosu na kućište (23, 123) kada je izvučena odmotavanjem željena dužina optičkog kabela (22, 122).
calculating the percentage of brominated tyrosine in the batch; and 
izračunavanje postotka bromiranog tirozina u glatiramer acetatu.
A compound of any one of items 1-16 for use in a method of treating cancer, comprising administering to a mammal having cancer a therapeutically effective amount of the compound. 
Spoj sukladno bilo kojem od zahtjeva 1 do 17, naznačen time, da se upotrebljava u postupku liječenja raka, postupak se sastoji u primjeni na sisavcu koji ima rak terapeutski učinkovite količine spoja.
For a proper spread of the liquid plastic material over a dry fiber package during injection, runner channels are necessary. 
Za pravilno rasprostiranje tekućeg plastičnog materijala po suhom vlaknastom tijelu tijekom brizganja su nužni protočni kanali.
We obtained similar results in our in vitro reflex test; dextromethorphan in the presence of tolperisone had higher reflex inhibitory activity, than alone, and the same potentiating effect was also demonstrated when a converse administration schedule was applied. 
Mi smo dobili slične rezultate u našim pokusima ispitivanja refleksa in vitro; dekstrometorfan je u prisutnosti tolperisona imao više djelovanje inhibitora refleksa nego sam, i isti učinak pojačavanja se je također pokazao kad se je primijenio obrnuti program davanja.
Vilhardt H. Basic pharmacology of desmopressin: a review. Drug Invest 1990; 2 (suppl 5): 2-8 A composition comprising desmopressin for use in treating a male patient having nocturia or nocturnal polyuria, by reducing the number of nocturnal voids in the male patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg, wherein the dose is measured as the free base of desmopressin, for administration prior to bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja nokturije 1l1 noćne poliurije, za smanjenje broja noćnih pražnjenja i/ili za smanjenje noćnog volumena urina i/ili za povećanje početnog razdoblja sna neometanog s noćnim pražnjenjima kod ženskog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina, naznačen time da se doza mjeri kao slobodna baza dezmopresina, pri čemu se doza uzima od 0,8 do 3 sata prije počinka pacijenta.
FIG. 2 is a plan view of the interior of a poultry shed in which the process according to the invention is implemented; 
Postupak sukladno Zahtjevu 12 u kojem se prostor za skladištenje goriva (7) sastoji od otvorenog skladišnog prostora susjednog aparatu za spaljivanje.
According to a preferred aspect, compounds of the invention are selected from the group consisting in: 
Prema poželjnom aspektu, spojeve prema ovom izumu se bira iz skupine koju čine:
The liquefied gas treatment system according to claim 2, wherein a gas-liquid separator is installed to separate only a liquid component from the third stream decompressed to a gas-liquid mixed state and return the liquid component to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (L24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
B is selected from the group consisting of (C1-6)alkyl, C(O)NR21R22, phenyl and heteroaryl; wherein said (C1-6)alkyl, phenyl and heteroaryl are independently optionally substituted with one to three same or different halogens or from one to three same or different substituents selected from F; heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, tetrazolyl and triazolyl; 
B se izabire iz skupine koja obuhvaća (C, .g)alkil, C(O)NR'R", fenil i heteroaril; a taj (Crs)alkil, fenil i heteroaril su nezavisno jedan od drugog po izboru supstituirani jednim do tri istih ili različitih halogena, ili jednim do tri istih ili različitih supstituenata izabranih između F; heteroaril se izabire iz skupine koja obuhvaća piridinil, pirazinil, piridazinil, pirimidinil, furanil, tienil, tiazolil, oksazolil, izoksazolil, imidazolil, oksadiazolil, tiadiazolil, pirazolil, tetrazolil i triazolil:
The RBAR system of claim 5 wherein the control unit interactively controls the fluid actuator to provide 5-25% of the stoichiometric amount of regeneration fluid required for hydration of the reactant particles in said bottom ash. 
Sustav RBAR prema zahtjevu 13 naznačen time da nadzorna jedinica interaktivno nadzire regulator fluida (135) da se dobije 5-25% stehiometrijske količine regeneracijskog fluida potrebnog za hidraciju reakcijskih čestica (10) u navedenom pepelu s dna peći (17).
The dry powder formulation according to claim 5, wherein the high-energy apparatus is a mechano-fusion apparatus. 
Formulacija suhog praška prema patentnom zahtjevu 5, naznačeno time da visokoenergijska aparatura jest mehano-fuzijska aparatura.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor invasiveness. 
40-O-(2-hidroksietil)-rapamicin, naznačen time, da se upotrebljava za obradu invazivnosti neuroendokrinog tumora pankreasa.
an aromatase inhibitor which is exemestane or letrozole. 
(b) inhibitor aromataze koji je eksemestan ili letrozol.
A pharmaceutical composition of Claim 6 further comprising an additional pharmaceutical agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što dodatno sadrži dodatno farmaceutsko sredstvo.
Yet a further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic inflammatory pain. One embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, IBS, pancreatitis or ischeamic. Another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of sciatia, diabetic neuropathy, multiple sclerosis or HIV neuropathy. 
Uporaba prema zahtjevu 12, naznačena time da joj je svrha liječenje akutne i kronične upalne boli. Uporaba prema zahtjevu 12, naznačena time da joj je svrha liječenje artritisa, fibromialgije, križobolje, postoperativne boli, visceralnih bolova poput kronične boli zdjelice, cistitisa, sindroma iritabilnog kolona (IBS), pankreatitisa, ishemije, išijasa, dijabetske neuropatije, multiple skleroze, intersticijalnog cistitisa i boli povezane sa intersticijalnim cistitisom, HIV neuropatije, astme, kašlja i upalne bolesti kolona (IBD), gestro-ezofagealne refluksnc bolesti (GERD), psorijaze, raka, cemeze, urinarne inkontinencije i hipcraktivnog mjehura.
The method of one of the preceding claims, wherein said receiving of at least one of said first and second OFDM transmissions comprises decoding said at least one of said first and second OFDM transmissions using a polar code. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedeno primanje najmanje jednog od navedenog prvog i drugog slanja OFDM sastoji u dekodiranju navedenog najmanje jednog od navedenog prvog i drugog slanja OFDM uz pomoć polarnog koda.
The formulation for parenteral administration consisting of a lyophilized formulation according to claim 13, wherein said lyophilized formulation is dissolved in a pharmaceutically acceptable reconstitution solution suitable for parenteral administration to a patient in need thereof. 
15. Formulacija za parenteralnu primjenu koja se sastoji od lipofilizirane formulacije prema zahtjevu 14, pri čemu se navedena lipofilizirana formulacija otapa u farmaceutski prihvatljivoj rekonstituiranoj otopini prikladnoj za parenteralnu primjenu u potrebitih pacijenata.
A compound according to claim 4 wherein RA is cyclopentyl or cyclohexyl. A compound according to claim 1 wherein R1 is RB, which is optionally substituted with one or more R7 groups. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time što R* je ciklopentil ili cikloheksil. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R! je R*, koji je izborno supstituiran s jednom ili više skupina R'.
The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide comprising the sequence of SEQ ID NO:3. 
vektor koji kodira optimizirani virusni polipeptid koji ima sekvencu amino kiselina prikazanu u SEQ ID NO:9.
an increase in glucose uptake by cells in the subject; 
(b) = povećanjem unosa glukoze u stanica kod subjekta;
A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having a X-ray powder diffraction pattern containing peaks at (± 0.2) 17.6, 18.4, 22.5 and 24.2 degrees 2-theta. 
Spoj prema zahtjevu 1, naznačen time da spoj s formulom (1) u krutom kristalnom obliku ima uzorak difrakcije X-zraka na prahu koji obuhvaća vrhove kod (+ 0.2) 17.6, 18.4, 22.5 i 24.2 stupnjeva 2-theta.
In one embodiment, the process recovers more than 40% or more than 50% pure IL-18BP after affinity chromatography. 
Postupak prema zahtjevu 10 ili 11, naznačen time da je obnavljanje IL-18BP više od oko 40% ili više od oko 50% nakon afinitetne kromatografije.
The compound according to Claim 1 which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 5-(5-(2-(3-aminopropoksi)-6-metoksifenil)-1H-pirazol-3-ilamino)pirazin-2-karbonitril, ili njegova farmaceutski prihvatljiva sol.
condensing the gaseous hydrogen chloride in one or more condensing chambers wherein the one or more condensing chambers comprise water. 
kondenziranje plinovitog klorovodika u jednoj ili više kondenzacijskih komora pri čemu jedna ili više kondenzacijskih komora obuhvaćaju vodu.
about 24 mg of said naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of said bupropion or a pharmaceutically acceptable salt thereof for the third week of treatment; and about 32 mg of said naltrexone or a pharmaceutically acceptable salt thereof and about 360 mg of said bupropion or a pharmaceutically acceptable salt thereof for the fourth and any subsequent weeks of treatment; or 
oko 24 mg naltreksona ili njegove farmaceutski prihvatljive soli i oko 270 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku trećeg tjedna tretmana; i oko 32 mg navedenog naltreksona ili njegove farmaceutski prihvatljive soli i oko 360 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku četvrtog tjedna tretmana i bilo kojeg slijedećeg tjedna tretmana.
The present invention also provides that quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof, can be prepared by a process (a) to (m) as follows (wherein the variables are as defined above unless otherwise stated): 
Ovim je izumom također navedeno da derivati kinazolina prikazani Formulom I, ili njihove farmaceutski prihvatljive soli, mogu biti pripravljeni postupcima (a) do (m) kako slijedi (pri tome su varijable u skladu sa definicijama u gornjem tesktu, osim ako nije navedeno drugačije):
Use according to claim 1, characterized in that the pre-menopausal Sexual Desire Disorder is selected from the group consisting of pre-menopausal Hypoactive Sexual Desire Disorder, pre-menopausal Sexual Aversion Disorder, pre-menopausal loss of sexual desire, pre-menopausal lack of sexual desire, pre-menopausal decreased sexual desire, pre-menopausal inhibited sexual desire, pre-menopausal loss of libido, pre-menopausal libido disturbance, and pre-menopausal frigidity. 
Uporaba u skladu sa zahtjevom 1, naznačena time, da je poremećaj seksualne želje u pre-menopauzi izabran iz skupine koju čine poremećaj hipoaktivne seksualne želje u pre-menopauzi, poremećaj seksualne averzije u pre-menopauzi, gubitak seksualne želje u pre-menopauzi, manjak seksualne želje u pre-menopauzi, smanjena seksualna želja u pre-menopauzi, inhibirana seksualna želja u pre-menopauzi, gubitak libida u pre-menopauzi, poremećaj libida u pre-menopauzi i frigidnost u pre-menopauzi-
Pharmaceutical compositions according to the invention may be administered as monotherapy or in combination with another pharmaceutical composition, preferably comprising another anti-neoplastic agent, in particular Cisplantin or Avastin. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 16 do 18 koji se može primijeniti kao monoterapija ili u kombinaciji s daljnjim farmaceutskim sastavom koji poželjno obuhvaća antineoplastični agens kao što je Cisplatin ili Avastin.
The compound, or a pharmaceutically acceptable salt or N-oxide derivative thereof as claimed in claim 2, wherein R1 is a hydrogen atom, or a C1-C6 alkyl group optionally substituted with a halogen atom or a hydroxyl group. 
Tvar, ili farmaceutski prihvatljiva sol ili njen N-oksid derivat u skladu s patentnim zahtjevom 1, gdje je R1 atom vodika, ili C1-C6 alkilna grupa opcionalno supstituirana s atomom halogena ili hidroksilnom grupom.
Use of the B cell of claim 12 to make a hybridoma comprising a rearranged immunoglobulin light chain gene sequence derived from the mouse of claim 1, the rearranged sequence comprising a hVλ gene segment, a hJλ gene segment operably linked to a mouse Ck gene segment at an endogenous mouse k immunoglobulin light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained, and where the hybridoma expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence. A mouse comprising: 
Primjena B stanice prema zahtjevu 12 za izradu hibridoma koji se sastoji od preuređene sekvencije gena lakog imunoglobulinskog lanca dobivene iz miša prema zahtjevu 1, preuređene sekvencije koja se sastoji od hVA segmenta gena, hJA segmenta gena funkcionalno povezanog s mišjim CK segmentom gena na mišjem lokusu endogenog lakog x imunoglobulinskog lanca, pri čemu se na spomenutom lokusu održava k element intronskog pojačivača uzlazno od CK gena (označeno kao Eki) 1 3'K pojačivač silazno od CK gena (označeno kao EK3'), i pri čemu hibridom izražava antitijelo koje se sastoji od lakog lanca koji sadrži preuređenu humanu VA-JA sekvenciju 1 mišju Cx sekvenciju.
a second polyol, the second polyol being selected from propylene glycol, glycerine or a combination thereof, and wherein the second polyol is at least about 0.1 but less than about 5 w/v % of the composition. 
drugi poliol, te je drugi poliol odabran od propilen glikola, glicerina ili njihove kombinacije, pri čemu je koncentracija drugog poliola najmanje 0,1 m/v% ali manja od 5 m/v% pripravka;
The composition of any one of claims 7 to 15, wherein the core additionally comprises a lubricant selected from stearic acid, a hydrogenated vegetable oil, paraffin or an alkali or alkaline earth stearate, aluminum stearate, sodium stearyl fumarate or a mixture of two or more of these compounds, preferably magnesium or calcium stearate, more magnesium potassium stearate. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da jezgra dodatno obuhvaća lubrikant odabran od stearinske kiseline, hidrogeniziranog biljnog ulja, parafina ili alkalijskog ili zemnoalkalijskog stearata, aluminijevog stearata, natrijevog stearil-fumarata ili mješavine od dva ili više tih spojeva, poželjno magnezijevog ili kalcijevog stearata.
Glucose isomerase for use by oral administration in the therapy of fructose intolerance; wherein the glucose isomerase is contained in acceptable excipients and/or carriers selected from maltodextrin, calcium carbonate, dicalcium phosphate, tricalcium phosphate, microcrystalline cellulose, dextrose, rice flour, magnesium stearate, stearic acid, croscarmellose sodium, sodium starch glycolate, crospovidone, sucrose, vegetable gums, lactose, methylcellulose, povidone, carboxymethyl cellulose, corn starch, modified starch, fibersol, gelatine, hydroxypropylmethyl cellulose and the like (including mixtures thereof); provided that the glucose isomerase is not used in combination with 5-D-fructose dehydrogenase for said therapy. 
Sredstvo sukladno patentnom zahtjevu 1, naznačeno time, da su farmaceutski prihvatljivi ekscipijenti i / ili nosači odabrani između maltodekstrina, kalcijevog karbonata, dikalcijevog fosfata, trikalcijevog fosfata, mikrokristalne celuloze, dekstroze, rižinog brašna, magnezijevog stearata, stearinske kiseline, natrijeve kroskarmeloze, glikolat, krospovidon, saharoza, biljne smole, laktoza, metilceluloza, povidon, karboksimetil celuloza, kukuruzni škrob, modificirani škrob, fibersol, želatina, hidroksipropilmetil celuloza i njihove smjese.
The antibody of claim 6, wherein the antibody comprises a substitution in an Fc region. 
Protutijelo sukladno patentnom zahtjevu 6, naznačeno time, da protutijelo sadrži supstituciju u Fc Tegiji.
The combined EtOAc extracts are washed with water, dried (Na2SO4) and evaporated to a yellow-orange solid. 
Sjedinjeni EtOAc ekstrakti se isperu s vodom, osuše se (Na»SO2) i ispare u žuto-narančastu krutu tvar.
A capsule according to any one of the preceding claims, wherein the projection is made of the same material as the cup. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je ispupčeni dio (127) napravljen od istog materijala kao čašica.
In one specific embodiment of the invention the anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment binding to adrenomedullin or anti-ADM non-Ig scaffold binding to adrenomedullin is provided for use in therapy of an acute disease or acute condition of a patient wherein said antibody or antibody fragment or non-Ig scaffold binds to a region of preferably at least 4, or at least 5 amino acids within the sequence of aa 1-42 of mature human ADM: SEQ ID NO: 24 
Protutijelo protiv adrenomedulina (ADM) ili fragment protutijela protiv ADM koji se veže na adrenomedulin ili okosnica ne-Ig protiv ADM koja se veže na adrenomedulin, namijenjeni upotrebi u terapiji akutne bolesti ili akutnog stanja kod pacijenta u skladu bilo kojim od patentnih zahtjeva 1 do 4, naznačeni time što navedeno protutijelo ili fragment ili okosnica dodatno pokazuju afinitet vezanja na ADM od najmanje 10" M, gdje se navedeni afinitet vezanja određuje kao u Primjeru 1.
and/or, in step (b), the reaction temperature for hydrazinolysis is in the range of 0-20° C.; 
i / ili, u koraku (b), reakcijska temperatura za hidrazinolizu je u rasponu od 0-20°C;
zeolites, molecular sieves, phosphates, zirconates, kaolinite, montmorillonite, pillared clays, hydrotalcites and acid ion-exchange resins; 
– zeoliti, molekulska sita, fosfati, cirkonati, kaoliniti, montmoriloniti, porozne gline, hidrotalciti i smole za kiselu ionsku izmjenu;
a first component, being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising: 
A) pripravak, izborno prisutan u dva ili više dijelova namijenjenih pripravi prve otopine za čišćenje debelog crijeva dodavanjem vode; 1
The composition according to claim 1, wherein the pharmaceutically active agent comprises one or more steroids selected from the group consisting of estrogens, antiestrogens, androgens, anti- androgens, and progestins. 
Pripravak prema zahtjevu 1, pri čemu farmaceutski aktivna tvar sadrži jedan 1li više steroida izabranih iz. skupine koja se sastoji od estrogena, antiestrogena, androgena, anti-androgena i progestina.